Lexicon Pharmaceuticals (LXRX) Cash & Current Investments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash & Current Investments data on file, last reported at $170.7 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $170.7 million, down 12.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $170.7 million (down 12.41% YoY), and the FY2025 annual result was $96.2 million, down 59.56% from the prior year.
• Cash & Current Investments rose to $170.7 million in Q1 2026 per LXRX's latest filing, from $96.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $355.6 million in Q1 2024 and troughed at $62.0 million in Q2 2022.
• A 5-year average of $179.6 million and a median of $170.0 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments soared 314.31% in 2023, then slumped 59.56% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $138.4 million in 2022, then advanced by 22.89% to $170.0 million in 2023, then surged by 39.95% to $238.0 million in 2024, then tumbled by 59.56% to $96.2 million in 2025, then jumped by 77.34% to $170.7 million in 2026.
• Business Quant data shows LXRX's Cash & Current Investments at $170.7 million in Q1 2026, $96.2 million in Q4 2025, and $116.0 million in Q3 2025.